Search clinical trials for: ABT-957

Total 4772 results

AbbVie

No longer available

Expanded Access to ABT-414

Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis
M.D. Anderson Cancer Center

Completed

Study of ABT-751 in Patients With Refractory Hematologic Malignancies

Hematological Malignancies

United States
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

United States, Canada, Singapore, Taiwan
Abbott

Terminated

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Completed

Exploratory Positron Emission Tomography (PET) Study to Evaluate the Effects of ABT-614 on [11C]-(+)-PHNO Binding Potential to D3 Receptors in the Brain

Healthy Volunteers

Canada
Abbott

Completed

A Study to Investigate the Process by Which ABT-614 is Absorbed, Distributed, Metabolized and Eliminated in Humans

Healthy

United States
Abbott

Completed

A Study of ABT-751 in Patients With Colorectal Cancer

Colorectal Cancer

United States
Abbott

Completed

A Study of ABT-751 in Patients With Renal Cell Cancer

Renal Cell Cancer

Canada, United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C (PEARL-II)

Chronic Hepatitis C Infection
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults (MALACHITE II)

Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis (TURQUOISE-II)

Compensated Cirrhosis | Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection (PEARL-III)

Chronic Hepatitis C Infection
VA Office of Research and Development

Recruiting

Treatments for Insomnia in Veterans With PTSD

PTSD | Insomnia

United States
Quintiles, Inc.

Unknown

Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy

Head and Neck Cancer

United States
Kathleen Ludwig

Available

Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients With Relapsed or Refractory ALL or LL

Relapsed Childhood ALL | Relapsed Childhood Lymphoblastic Lymphoma

United States
AbbVie

Completed

Bioavailability of ABT-450 and ABT-267 With Ritonavir

Absolute Bioavailability

United Kingdom
AbbVie

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection

Chronic Hepatitis C | Hepatitis C Virus
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (CERTAIN-2)

Hepatitis C Virus | Chronic Hepatitis C Virus
Abbott

Completed

Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

United States, Netherlands
Abbott

Completed

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Lymphoma, Non-Hodgkin | Hodgkin's Lymphoma

United States
AbbVie

Recruiting

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Hidradenitis Suppurativa

United States, Australia, Canada, Germany, Greece, Japan, Spain, Puerto Rico
University of Florida
National Heart, Lung, and Blood Institute (NHLBI); StayWell; WellCare Health...

Completed

Wellness Achieved Through Changing Habits (The WATCH Study)

Obesity | Overweight | Weight Loss

United States
AbbVie

Completed

Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder

Major Depressive Disorder
AbbVie

No longer available

Expanded Access to Navitoclax

Myelofibrosis | Lymphoblastic Lymphoma | Acute Lymphocytic Leukemia (ALL)

United States
AbbVie

Completed

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection (ENDURANCE-5 6)

Hepatitis C Virus (HCV)

United States, Australia, Belgium, Canada, France, New Zealand, Singapore, South Africa, Vietnam
Anbogen Therapeutics, Inc.

Recruiting

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

Non Small Cell Lung Cancer | Advanced Solid Tumor | HER2 Mutations

Taiwan
AbbVie (prior sponsor, Abbott)

Completed

A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

Schizophrenia

United States
AbbVie

Completed

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

Acute Kidney Injury

United States, Denmark
AbbVie (prior sponsor, Abbott)

Completed

Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Cognitive Deficits in Schizophrenia

United States
AbbVie

Completed

An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors

Advanced Solid Tumors
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee

Osteoarthritis

United States
AbbVie

Terminated

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery

Cardiothoracic Surgery | Vascular Surgery

United States, Denmark
AbbVie (prior sponsor, Abbott)

Completed

Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Terminated

A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States
Abbott

Completed

To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.

Advanced Solid Tumors

United States
Abbott

Completed

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Completed

A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy Adults

Healthy

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953

Healthy

Japan
National Cancer Institute (NCI)

Terminated

CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

Thyroid Neoplasms | Differentiated Thyroid Cancer | Poorly Differentiated and Undifferentiated Thyroid Cancer

United States
UCB Pharma

Completed

A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy

Diabetic Neuropathy

United States
UCB Pharma

Completed

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

Partial Seizures With or Without Secondary Generalization

Germany
UCB Pharma

Completed

SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

Epilepsy
Akros Pharma Inc.

Completed

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

Anemia in Chronic Kidney Disease

United States
Advanced Life Sciences, Inc.

Unknown

Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma

Melanoma

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (PEARL-I)

Hepatitis C, Chronic
Vanderbilt-Ingram Cancer Center

Terminated

Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer

Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal Cancer

United States
University of Arkansas

Withdrawn

Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer

Carcinoma, Non-Small-Cell-Lung

United States
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)

Completed

Affective Management Training for Cannabis Misuse

Cannabis Use Disorder

United States
Drugs for Neglected Diseases
UNITAID; French Development Agency

Completed

Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study) (LIVING)

HIV

Uganda, Kenya, Tanzania
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment (EXPEDITION-5)

Hepatitis C Virus (HCV)

United States, Canada, Germany, Greece, Italy, Korea, Republic of, Poland, Puerto Rico, Spain, Sweden

3

Subscribe